SG11201507135XA - Methods of maintaining and improving muscle function - Google Patents

Methods of maintaining and improving muscle function

Info

Publication number
SG11201507135XA
SG11201507135XA SG11201507135XA SG11201507135XA SG11201507135XA SG 11201507135X A SG11201507135X A SG 11201507135XA SG 11201507135X A SG11201507135X A SG 11201507135XA SG 11201507135X A SG11201507135X A SG 11201507135XA SG 11201507135X A SG11201507135X A SG 11201507135XA
Authority
SG
Singapore
Prior art keywords
maintaining
methods
muscle function
improving muscle
improving
Prior art date
Application number
SG11201507135XA
Other languages
English (en)
Inventor
Sean Garvey
Suzette Pereira
Neile Edens
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SG11201507135XA publication Critical patent/SG11201507135XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/42—Preservation of non-alcoholic beverages
    • A23L2/50—Preservation of non-alcoholic beverages by irradiation or electric treatment without heating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11201507135XA 2013-03-15 2014-03-14 Methods of maintaining and improving muscle function SG11201507135XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792489P 2013-03-15 2013-03-15
US201361823832P 2013-05-15 2013-05-15
PCT/US2014/028879 WO2014144458A1 (en) 2013-03-15 2014-03-14 Methods of maintaining and improving muscle function

Publications (1)

Publication Number Publication Date
SG11201507135XA true SG11201507135XA (en) 2015-10-29

Family

ID=50555279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507135XA SG11201507135XA (en) 2013-03-15 2014-03-14 Methods of maintaining and improving muscle function

Country Status (11)

Country Link
US (1) US9844531B2 (pt)
EP (1) EP2986158A1 (pt)
JP (1) JP2016517438A (pt)
CN (1) CN105431057A (pt)
BR (1) BR112015023031A2 (pt)
CA (1) CA2903565A1 (pt)
HK (1) HK1221611A1 (pt)
MX (1) MX2015013000A (pt)
PH (1) PH12015502167A1 (pt)
SG (1) SG11201507135XA (pt)
WO (1) WO2014144458A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
WO2016044272A1 (en) * 2014-09-16 2016-03-24 Abbott Laboratories Methods of preserving muscle strength during a period of muscle disuse by administering beta-hydroxy-beta-methylbutyrate and green tea extract
JP6796070B2 (ja) * 2015-09-30 2020-12-02 協同乳業株式会社 難消化性成分を含む飲食品および大腸内水素ガス産生剤
US20170196824A1 (en) * 2016-01-13 2017-07-13 Metabolic Technologies, Inc. Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for joint stability
CN114767870A (zh) * 2016-05-27 2022-07-22 雀巢产品有限公司 用于治疗或预防移动性受损的营养组合物
WO2018075867A1 (en) * 2016-10-21 2018-04-26 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) AND PROBIOTICS
ES2930013T3 (es) 2017-03-31 2022-12-05 Abbott Lab Composiciones nutricionales líquidas que contienen aceite de pescado oxidable, ácido rosmarínico y hierro férrico
US20200163370A1 (en) 2017-08-03 2020-05-28 Abbott Laboratories Liquid nutritional compositions including green tea extract and iron
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
KR102281263B1 (ko) * 2019-03-12 2021-07-26 주식회사 비티씨 갈릭산, 에피카테킨(ec), 및 에피갈로카테킨(egc)의 함량이 증가된 카테킨 효소처리물 및 이의 제조방법
US20210228657A1 (en) * 2019-04-23 2021-07-29 Glac Biotech Co., Ltd. Food composition and pharmaceutical composition used for increasing exercise performance and ameliorating fatigue
BR112021024633A2 (pt) * 2019-07-05 2022-01-18 Nestle Sa Composições e métodos que usam trigonelina e vitaminas para evitar ou tratar condições ou distúrbios no músculo esquelético
US20220312818A1 (en) * 2019-07-25 2022-10-06 Korea University Research And Business Foundation Preparation method for two-spotted cricket powder or extract thereof, food composition comprising same, and uses of same
CN111000233A (zh) * 2019-11-28 2020-04-14 湖南农业大学 Ecg作为健肌功能成分的应用
CN110839890B (zh) * 2019-12-03 2022-06-21 湖南农业大学 一种茶黄素健肌的膳食营养补充剂的及其制备方法
CN115348821A (zh) * 2020-03-10 2022-11-15 加利福尼亚大学董事会 增强负荷诱导的肌肉肥大的新型营养物
KR20220015769A (ko) * 2020-07-31 2022-02-08 고려대학교 산학협력단 그릴루스 비마쿨라투스를 유효성분으로 포함하는 근위축증의 예방, 개선 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1039892B1 (en) 1997-02-21 2004-04-28 Abbott Laboratories Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
NZ533439A (en) 2001-12-19 2006-06-30 The Quigley Corp Methods for the treatment of peripheral neural and vascular ailments using flavonoid compositions
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US20040138118A1 (en) 2002-09-16 2004-07-15 Neil Wolfman Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
JP2006131512A (ja) 2004-11-02 2006-05-25 Pharma Foods International Co Ltd アディポネクチン分泌促進組成物および該組成物を含有する飲食品
FR2882896B1 (fr) 2005-03-14 2007-05-04 Larena Sa Composition alimentaire pour prevenir le syndrome de fragilite chez les personnes agees
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
KR20080105023A (ko) * 2005-10-14 2008-12-03 디에스엠 아이피 어셋츠 비.브이. 근육 소모의 치료를 위한 기능성식품 조성물
US20090163579A1 (en) 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
EP1945047A1 (en) * 2005-11-08 2008-07-23 Accelis Fomulations Ltd. Diet supplement and method for weight-loss
KR101558231B1 (ko) 2006-05-01 2015-10-08 (주)아모레퍼시픽 (-)카테친을 함유하는 아디포넥틴 발현 증강제
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2036552B1 (en) 2006-07-05 2018-08-08 Kao Corporation Senescence inhibitor
JP2008013473A (ja) * 2006-07-05 2008-01-24 Kao Corp 筋機能低下抑制剤
CN101484157B (zh) * 2006-07-05 2012-02-29 花王株式会社 肌肉力量提高剂
EP1961310A1 (en) * 2007-02-01 2008-08-27 DSMIP Assets B.V. Novel use of (-) -epigallocatechin gallate
US20100210692A1 (en) 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators
WO2009008991A2 (en) * 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
BRPI0811317A2 (pt) 2007-08-03 2015-01-27 Summit Corp Plc Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação
JP2009120491A (ja) 2007-11-12 2009-06-04 Tsujido Kagaku Kk アディポネクチン産生促進剤
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
CN104997774A (zh) 2009-04-10 2015-10-28 齐海燕 新的抗衰老试剂及其鉴别方法
US20100303937A1 (en) 2009-06-01 2010-12-02 Michael Farber Novel composition to increase testosterone levels
EP2440201A1 (en) 2009-06-10 2012-04-18 Energy4life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
JP2012533627A (ja) 2009-07-20 2012-12-27 ネステク ソシエテ アノニム 機能状態の喪失を減弱する方法
US9162014B2 (en) 2010-01-25 2015-10-20 Concept Medical Research Private Limited Method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent
WO2013142816A1 (en) 2012-03-23 2013-09-26 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders
WO2014028607A1 (en) * 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
WO2014055905A1 (en) 2012-10-04 2014-04-10 Abbott Laboratories Methods for enhancing the effect of egcg on mitigating skeletal muscle loss

Also Published As

Publication number Publication date
HK1221611A1 (zh) 2017-06-09
US20160038457A1 (en) 2016-02-11
CA2903565A1 (en) 2014-09-18
JP2016517438A (ja) 2016-06-16
MX2015013000A (es) 2015-12-01
BR112015023031A2 (pt) 2017-07-18
WO2014144458A1 (en) 2014-09-18
PH12015502167A1 (en) 2016-01-25
US9844531B2 (en) 2017-12-19
CN105431057A (zh) 2016-03-23
EP2986158A1 (en) 2016-02-24

Similar Documents

Publication Publication Date Title
HK1221611A1 (zh) 維持和改善肌肉功能的方法
IL290547A (en) Antibodies and methods of use
HK1216380A1 (zh) 附接裝置以及使用和製造的相關聯的方法
HK1223913A1 (zh) 經取代的苯甲酰胺及其使用方法
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
IL244495B (en) Anti-alpha-synuclein antibodies and methods of use
IL286759A (en) Therapeutic methods and preparations
GB201320723D0 (en) Composition and methods of treatment
PL2968100T3 (pl) Kombinacje amidotiazoli alkilowych i konserwantów
EP2999474A4 (en) THERAPEUTIC AND METHOD OF USE
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
HK1209324A1 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
HK1225612A1 (zh) 抗ly6e抗體及使用方法
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1223608A1 (zh) 嗎泛和嗎啡喃類似物和其用途
HK1218388A1 (zh) 奧那司酮多晶型形式和使用方法
GB201319255D0 (en) Therapeutic compositions and methods
GB201321848D0 (en) Lock means and method of use thereof
ZA201305839B (en) Containers and methods of erectiing containers
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof